Monte Rosa reports positive phase 1 data for MRT-8102
Monte Rosa Therapeutics, Inc. announced positive Phase 1 results for its investigational drug MRT-8102, a molecular glue degrader targeting the NEK7 protein. The study involved 108 obese individuals with elevated cardiovascular disease risk, who received once-daily doses of MRT-8102 or placebo for eight weeks. Across all three doses (5 mg, 20 mg, and 40 mg), MRT-8102 achieved median NEK7 degradation of 80% to 90%.
The treatment reduced several biomarkers linked to atherosclerotic cardiovascular disease, including calprotectin, S100A12, SAA, HMGB1, IL-1β, IL-6, and hsCRP. Notably, MRT-8102 did not raise LDL-C or triglyceride levels and was well-tolerated, with no serious adverse events reported. The company plans further studies in coronary artery disease, gout, and hidradenitis suppurativa.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
